PD11-03 THE USE OF PHOSPHODIESTERASE 5 INHIBITORS IS NOT ASSOCIATED WITH OCULAR ADVERSE EVENTS

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD11-03 THE USE OF PHOSPHODIESTERASE 5 INHIBITORS IS NOT ASSOCIATED WITH OCULAR ADVERSE EVENTS Federico Belladelli, Shufeng Li, Chiyuan A. Zhang, Francesco Del Giudice, Frank Glover, Wade Muncey, Nicolas Serranio, Satvir Basran, Francesco Montorsi, Andrea Salonia, and Michael Eisenberg Federico BelladelliFederico Belladelli More articles by this author , Shufeng LiShufeng Li More articles by this author , Chiyuan A. ZhangChiyuan A. Zhang More articles by this author , Francesco Del GiudiceFrancesco Del Giudice More articles by this author , Frank GloverFrank Glover More articles by this author , Wade MunceyWade Muncey More articles by this author , Nicolas SerranioNicolas Serranio More articles by this author , Satvir BasranSatvir Basran More articles by this author , Francesco MontorsiFrancesco Montorsi More articles by this author , Andrea SaloniaAndrea Salonia More articles by this author , and Michael EisenbergMichael Eisenberg More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003251.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Phosphodiesterase-5 inhibitors (PDE5i) are the first-line line treatment for men with ED. The use of PDE5I has recenty been linked to several ocular side effects, such as serous retinal detachment (SRD), retinal vascular occlusion (RVO), and ischemic optic neuropathy (ION). However, the risk factors for major ocular events and ED overlap suggesting that the association may not be causative. The current study investigated the risk for SRD, RVO, and ION in patients using PDE5Is. METHODS: We utilized the IBM® MarketScan® (2007 to 2016) Commercial and Medicare Supplemental Databases (v 2.0, DOI: 10.57761/ray7-1g16). Cox proportional hazard models were applied to calculate the risk of ocular events after the diagnosis and or treatment of ED (i.e. PDE5i, penile injection/urethral suppositories, penile prosthesis placement) while adjusing for relevant comorbidities. As a further analysis, the use of PDE5i in men with BPH was also examined. RESULTS: In total, 1,565,006 men with an ED diagnosis were identified. Among them, 525,624 (33.6%) were treated with a PDE5i. In total, 1,806,803 men with a BPH diagnosis were observed during the study period with 141,607 (7.8%) treated with a PDE5i. On adjusted analysis, PDE5i use was not consistently associated with SRD, ION, and any ocular event when compared to ED diagnosis and other ED treatments. However, men who received a penile prosthesis had a higher risk of ocular events RVO (HR: 2.36; 95% CI: 1.81–3.09). In addition, PDE5i use was associated with SRD, RVO, and ION in the BPH cohort. In fact, BPH patients using 5a reductase/alpha blocker or prostatectomy had the highest risk of ocular events. CONCLUSIONS: In the current report, no consistent association with PDE5i use and adverse ocular events (i.e. SRD, RVO, and ION) was identified. For erectile dysfunction, men requiring more invasive treatment of ED (i.e. men with more severe ED who required more invasive treatments) carried the highest risk of adverse ocular events. The link between PDE5i use and ocular events is consistent with biases related to common risk factors suggesting patient counseling about this association is unnecessary. Source of Funding: Data for this project were accessed using the Stanford Center for Population Health Sciences Data Core. The PHS Data Core is supported by a National Institutes of Health National Center for Advancing Translational Science Clinical and Translational Science Award (UL1TR003142) and from Internal Stanford funding. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e333 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Federico Belladelli More articles by this author Shufeng Li More articles by this author Chiyuan A. Zhang More articles by this author Francesco Del Giudice More articles by this author Frank Glover More articles by this author Wade Muncey More articles by this author Nicolas Serranio More articles by this author Satvir Basran More articles by this author Francesco Montorsi More articles by this author Andrea Salonia More articles by this author Michael Eisenberg More articles by this author Expand All Advertisement PDF downloadLoading ...